Abbott, Dexcom settle global CGM patent litigation
Dec 23, 2024 · Left, the Dexcom G7 CGM. Right, the Abbott FreeStyle Libre 2. [Images from Dexcom and Abbott] Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies.
Dexcom launches generative AI platform for glucose biosensing
Dec 17, 2024 · A pickleball player wears the Stelo over-the-counter CGM. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its glucose biosensing technology. San Diego-based Dexcom says this makes it the first continuous glucose monitor (CGM) …
BD hit with FDA warning related to Pyxis medication management
Dec 23, 2024 · The FDA has issued a warning letter related to BD Pyxis automated medication dispensing systems — technology that was part of its $12 billion CareFusion acquisition in 2015.. The warning letter, dated Nov. 22 and posted on Dec. 17, involves inspections conducted in May at a former CareFusion facility in San Diego.
European court rules in favor of Abbott in Dexcom CGM patent spat
Dec 12, 2024 · Left, the Dexcom G7 CGM. Right, the Abbott FreeStyle Libre 2. [Images from Dexcom and Abbott] The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim from Dexcom (Nasdaq:DXCM). Abbott and Dexcom are two leaders in the continuous glucose monitoring (CGM) space.
These diabetes devices are set to launch in 2024 - Drug Delivery …
Feb 27, 2024 · The Stelo glucose monitor for people with diabetes who are not taking insulin. [Image courtesy of Dexcom] The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year.Some of those stories didn’t end in 2023, though ...
Medtronic to submit to FDA for type 2 diabetes in 2025
Nov 19, 2024 · The MiniMed 780G with the Guardian 4 sensor. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) has plans to submit its MiniMed 780G for an expanded indication from the FDA for type 2 diabetes in the near future. On the company’s second-quarter earnings call, Que Dallara, EVP and president of Medtronic Diabetes outlined the progress on that front.
Vivani Medical initiates first-in-human GLP-1-eluting implant study
Dec 19, 2024 · The Vivani NanoPortal technology. [Image courtesy of Vivani] Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight subjects.
The biggest diabetes tech stories of the year so far
Nov 14, 2024 · Some of the diabetes technology included in the most-read stories of the year. [Images courtesy of Dexcom, Abbott, Senseonics, Insulet, Sequel Med Tech, Tandem Diabetes Care and Medtronic] On World Diabetes Day, it’s worth taking a look back at the last 10.5 months in the diabetes technology space. The date, which marks the birth date of the inventor of insulin, brings out all sorts of ...
The 9 largest diabetes technology companies in the world
Aug 21, 2024 · Technologies from Abbott, Dexcom, Medtronic and Insulet. These companies are the four largest diabetes technology companies in the world. [Images courtesy of the companies] Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in …
FDA approves Abbott CGMs for use during medical imaging
Oct 30, 2024 · The FreeStyle Libre 3 Plus worn during an imaging procedure. [Image courtesy of Abbott] Abbott (NYSE:ABT) announced today that the FDA said users can wear the FreeStyle Libre 2 and 3 CGMs during common imaging procedures. The FDA cleared the removal of the imaging contradiction for the continuous glucose monitors (CGMs) for procedures like X-rays, CT scans and MRIs.